322TiP ENCEFALO (GEM2301) clinical trial: Encorafenib and binimetinib followed by cemiplimab and fianlimab in BRAF-mutant melanoma and symptomatic brain metastases
Year: 2025
Type: article
Abstract: Patients (pts) with BRAF-mutant melanoma symptomatic brain metastases (MBM) have a high unmet medical need. Targeted therapy (TT) has shown high intracranial response rates (RR) in this population independent of the symptomatic status. Encorafenib (E) and binimetinib (B) showed an ORR over 60% in pts with symptomatic brain metastasis. However, the duration of responses with TT remains short-termed in most cases. Conversely, immunotherapy (IT) shows low RR but is capable of achieving long-term disease control, mostly in asymptomatic pts.
Source: Immuno-Oncology Technology
Authors: I. Marquez-Rodas, M. Bringas, M. Sotelo, P. Ayala de Miguel, M.D.C. Alamo De La Gala, G. Crespo, P.C. Cerezuela-Fuentes, A. Arance, A. Soria, C. Aguado de la Rosa, E. Pérez-Ruiz, L. Egaña, I. González-Barrallo, E. Muñoz-Couselo, J. Martin-Liberal, L. Gutiérrez Sanz, M. Quindós, M. Gonzalez-Cao, A. Berrocal
Institutions: Hospital General Universitario Gregorio Marañón, Marqués de Valdecilla University Hospital, Hospital San Pedro de Alcántara, Hospital Universitario Virgen Macarena, Hospital Universitario de Burgos, Instituto Murciano de Investigación Biosanitaria, Hospital Universitario Virgen de la Arrixaca, Hospital Clínic de Barcelona, Hospital Universitario Ramón y Cajal, Hospital Clínico San Carlos, Hospital Regional Universitario de Málaga, Instituto de Investigación Biomédica de Málaga, Donostiako Unibertsitate Ospitalea, Hospital Clínico Universitario de Valencia, INCLIVA Health Research Institute, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Català d'Oncologia, Hospital Universitario Puerta de Hierro Majadahonda, Complexo Hospitalario Universitario A Coruña, Instituto de Investigación Biomédica de A Coruña, Instituto Oncológico Dr. Rosell, Hospital Universitario Dexeus, Hospital General Universitario De Valencia
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,340
OpenAlex ID: W7117292556